Strategies with a high degree of agreement are shaded gray. CTL, cytotoxic T lymphocyte; PCR, polymerase chain reaction; TCD, T-cell depletion; UCB, umbilical cord blood.

∗As of 11 May 2022.

†Continuation of prophylaxis at >1 year is based on risk for VZV reactivation.

‡CD4 T cells >200 cells/μL; CD19 B cells >50 cells/μL; immunoglobulin G >400 mg/dL; >8 weeks after last dose of IV immunoglobulin; minimum PHA of 40%; >6 months after last dose of rituximab.

§Determined by the transplant physician and dependent on time posttransplant, donor type, and availability of donor leukocytes or donor EBV specific CTLs and suspicion of PTLD.

‖High risk setting: ADV viral load: <day 30, >200 copies/mL; day 30 to 100, >1000 copies/mL; >day 100, >10 000 copies/mL.